About the Breast Cancer Conference
The Annual Breast Cancer Conference, presented by the Vermont Cancer Center at UVM/Fletcher Allen, is committed to serving the needs of men and women in Vermont, New Hampshire, and Northern New York who are interested in learning about breast health. The conference is also strongly attended by many of the region’s healthcare professionals. In 2012, nearly 800 people attended the event, with representation from several New England states, including every county in Vermont, and nearly all counties of New Hampshire and Northern New York.
Conference participants to make healthy lifestyle choices to prevent cancer or its recurrence, to seek breast health maintenance, and to advocate for cancer prevention and high-quality breast care in our region. The primary goal for the conference is to be a trusted resource of information and educational opportunities for as many individuals as possible who have been touched by cancer, and their families, friends, and healthcare providers. Tantamount to that goal are the objectives of providing attendees with the most accurate and timely information available regarding the complex issues related to breast cancer and to inspire participants to maintain a healthy lifestyle, proactively seek healthcare maintenance, and advocate for high-quality breast care and health.
Our hope is that attendees will leave the event feeling more informed about their health and the myriad complexities of breast cancer, more empowered to make healthy lifestyle choices, and stronger and more hopeful for their experience of attending the conference.
About the Vermont Cancer Center
The Vermont Cancer Center (VCC) is a nationally recognized comprehensive clinical and research cancer center committed to innovative cancer research, life-saving prevention and treatment programs, public education, and scientific collaboration. With more than 120 scientists engaged in a full range of basic, translational, clinical, and outcomes research, the institution plays an important role in Vermont and northern New York, influencing standards of cancer prevention and treatment across the region. VCC research is conducted primarily at the University of Vermont, and high-quality patient care is provided through the VCC’s clinical care partnership with Fletcher Allen Health Care.
Vermont Cancer Center physicians and scientists are contributing enormously to advances in cancer research in ways that are vital to understanding, preventing, diagnosing, and treating this disease. Some of our scientists' accomplishments related to breast cancer research include:
- Pioneering Radiotracer-Guided Sentinel Node Biopsy: A world-renowned researcher, David Krag, M.D., is best known for his revolutionary work in developing a sentinel node biopsy procedure that has become an international standard of care for patients. He is also the lead investigator with the National Adjuvant Surgical Breast and Bowel Program, of a Phase III randomized clinical trial of sentinel node dissection, the largest surgical breast cancer study in the world.
- Understanding Cognitive Effects of Chemotherapy: Physician-scientist Kim Dittus, M.D., Ph.D., is working with colleagues to help breast cancer patients and clinicians better understand the cognitive symptoms commonly known as “chemo brain,” which can occur when patients receive life-saving chemotherapy treatment.
- Helping in the Discovery of the Inherited Risk Factors for Breast Cancer: Since 2003, more than 400 women throughout the region have participated in the High-Risk Breast Program of Vermont, an effort that engages women connected to the Breast Care Center at the Vermont Cancer Center/Fletcher Allen in special research studies. Hereditary cancer specialist Marie Wood, M.D., and a team of clinicians and researchers work to ensure that women at an increased risk of developing breast cancer have access to consistent, state-of-the-art, high-risk breast cancer screening and prevention options.
- Preventing Chemo-Induced Side Effects: Steven Grunberg, M.D., recently published promising results from an international study he led that found adding a novel drug therapy to a conventional two-drug therapy resulted in a significant reduction in nausea and vomiting in cancer patients, particularly during the 24 to 120 hours following chemotherapy.
- Addressing Issues of Survivorship: A first-of-its-kind study led by public health researcher Berta Geller, Ed.D., is engaging Vermont’s cancer survivor community in an effort to educate researchers and health care and support service providers about the myriad issues facing cancer survivors. Funded by the National Cancer Institute, the study will help Geller determine how best to survey cancer survivors across Vermont and has facilitated the development of a database of cancer survivors who are interested in participating in future research studies.
Last modified December 09 2013 08:36 AM